All cancers VTE - Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Direct Oral AntiCoagulants (DOAC) therapy with edoxaban, apixaban, rivaroxaban, or dabigatran. The comparator is low molecular weight heparin (LMWH) alone or with warfarin. The information gained will empower cancer patients and physicians to make more informed choices about anticoagulation strategies to manage VTE.

Learn more at Clinicaltrials.gov NCT02744092

Adult Brain Cancer, Adult Breast Cancer, Cancer, Adult Gastrointestinal Cancer, Adult Gynecologic Malignancies, Adult Hematologic Malignancies, Adult Lung Cancer, Adult Multiple/Other Cancers